TY - JOUR
T1 - Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCG
AU - Numakura, Kazuyuki
AU - Miyake, Makito
AU - Kobayashi, Mizuki
AU - Muto, Yumina
AU - Sekine, Yuya
AU - Nishimura, Nobutaka
AU - Iida, Kota
AU - Shiga, Masanori
AU - Morizane, Shuichi
AU - Yoneyama, Takahiro
AU - Matsumura, Yoshiaki
AU - Abe, Takashige
AU - Yamada, Takeshi
AU - Matsumoto, Kazumasa
AU - Inokuchi, Junichi
AU - Nishiyama, Naotaka
AU - Taoka, Rikiya
AU - Kobayashi, Takashi
AU - Kojima, Takahiro
AU - Kitamura, Hiroshi
AU - Nishiyama, Hiroyuki
AU - Fujimoto, Kiyohide
AU - Habuchi, Tomonori
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/4
Y1 - 2023/4
N2 - Upper urinary tract urothelial carcinoma (UTUC) after intravesical bacillus Calmette-Guerin (BCG) therapy is rare, and its incidence, clinical impact, and risk factors are not fully understood. To elucidate the clinical implications of UTUC after intravesical BCG therapy, this retrospective cohort study used data collected between January 2000 and December 2019. A total of 3226 patients diagnosed with non-muscle-invasive bladder cancer (NMIBC) and treated with intravesical BCG therapy were enrolled (JUOG-UC 1901). UTUC impact was evaluated by comparing intravesical recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) rates. The predictors of UTUC after BCG treatment were assessed. Of these patients, 2873 with a medical history that checked UTUC were analyzed. UTUC was detected in 175 patients (6.1%) during the follow-up period. Patients with UTUC had worse survival rates than those without UTUC. Multivariate analyses revealed that tumor multiplicity (odds ratio [OR], 1.681; 95% confidence interval [CI], 1.005–2.812; p = 0.048), Connaught strain (OR, 2.211; 95% CI, 1.380–3.543; p = 0.001), and intravesical recurrence (OR, 5.097; 95% CI, 3.225–8.056; p < 0.001) were associated with UTUC after BCG therapy. In conclusion, patients with subsequent UTUC had worse RFS, CSS, and OS than those without UTUC. Multiple bladder tumors, treatment for Connaught strain, and intravesical recurrence after BCG therapy may be predictive factors for subsequent UTUC diagnosis.
AB - Upper urinary tract urothelial carcinoma (UTUC) after intravesical bacillus Calmette-Guerin (BCG) therapy is rare, and its incidence, clinical impact, and risk factors are not fully understood. To elucidate the clinical implications of UTUC after intravesical BCG therapy, this retrospective cohort study used data collected between January 2000 and December 2019. A total of 3226 patients diagnosed with non-muscle-invasive bladder cancer (NMIBC) and treated with intravesical BCG therapy were enrolled (JUOG-UC 1901). UTUC impact was evaluated by comparing intravesical recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) rates. The predictors of UTUC after BCG treatment were assessed. Of these patients, 2873 with a medical history that checked UTUC were analyzed. UTUC was detected in 175 patients (6.1%) during the follow-up period. Patients with UTUC had worse survival rates than those without UTUC. Multivariate analyses revealed that tumor multiplicity (odds ratio [OR], 1.681; 95% confidence interval [CI], 1.005–2.812; p = 0.048), Connaught strain (OR, 2.211; 95% CI, 1.380–3.543; p = 0.001), and intravesical recurrence (OR, 5.097; 95% CI, 3.225–8.056; p < 0.001) were associated with UTUC after BCG therapy. In conclusion, patients with subsequent UTUC had worse RFS, CSS, and OS than those without UTUC. Multiple bladder tumors, treatment for Connaught strain, and intravesical recurrence after BCG therapy may be predictive factors for subsequent UTUC diagnosis.
KW - BCG
KW - intravesical recurrence
KW - multiple bladder tumors
KW - non-muscle-invasive bladder cancer
KW - upper urinary tract cancer
UR - http://www.scopus.com/inward/record.url?scp=85152554101&partnerID=8YFLogxK
U2 - 10.3390/cancers15072002
DO - 10.3390/cancers15072002
M3 - 学術論文
C2 - 37046663
AN - SCOPUS:85152554101
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 7
M1 - 2002
ER -